The historic rise of Viagra has consistently remained a symbol of pharmaceutical success, but its legacy within the broader sector now raises questions about long-term gains. Alternative versions are undercutting patent protection , prompting concerns that investing in companies heavily reliant to Viagra's previous position could be a problematic d